---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-040387"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:02:41.495678+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics FDA accepts FDRR for ONS-5010; meeting set for April 2026

## Summary
- FDA accepted Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab) for wet AMD.
- Meeting with deciding official scheduled for April 2026; follows Type A meeting on March 2, 2026.
- Company cites NORSE TWO and NORSE EIGHT data supporting efficacy/safety; no safety concerns raised.
- If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with standardized manufacturing.

## SEC filing metadata
- accession: 0001104659-26-040387
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/0001104659-26-040387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926040387/tm2611268d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-040387
- JSON: https://secwatch.observer/filing/0001104659-26-040387.json
- Plain text: https://secwatch.observer/filing/0001104659-26-040387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.